Table 3 Differences between treatments (ratio for FEV1 and FVC, absolute values for other variables) for spirometric and other parameters
Variable | 9 μg vs. Placebo (p-value) | 4.5 μg vs. Placebo (p-value) | 9 μg vs. 4.5 μg (p-value) |
|---|---|---|---|
60-min post-dose FEV1, L | 1.11 (< 0.001) | 1.11 (< 0.001) | 1.01 (0.643) |
Pre-dose FEV1, L | 1.04 (0.002) | 1.04 (0.002) | 1.00 (0.955) |
5-min post-dose FEV1, L | 1.09 (< 0.001) | 1.09 (< 0.001) | 1.00 (0.984) |
60-min post-dose FVC, L | 1.07 (< 0.001) | 1.07 (< 0.001) | 0.99 (0.642) |
Pre-dose FVC, L | 1.02 (0.135) | 1.03 (0.026) | 0.99 (0.483) |
5-min post-dose FVC, L | 1.07 (< 0.001) | 1.07 (< 0.001) | 1.00 (0.982) |
Morning PEF, L/min | 15.30 (< 0.001) | 12.86 (< 0.001) | 2.45 (0.360) |
Evening PEF, L/min | 13.78 (< 0.001) | 10.85 (< 0.001) | 2.93 (0.260) |
Night-time awakening, score/day | -0.09 (0.038) | -0.10 (0.020) | 0.01 (0.816) |
Breathlessness, score/day | -0.17 (0.002) | -0.18 (0.001) | 0.01 (0.822) |
Cough, score/day | -0.13 (0.013) | -0.12 (0.023) | -0.01 (0.809) |
Total symptom score | -0.41 (0.001) | -0.62 (0.001) | -0.25 (0.883) |
Use of salbutamol, inhalations/day | -0.55 (< 0.001) | -0.27 (0.027) | -0.27 (0.029) |
SGRQ total score | -4.45 (0.001) | -3.74 (0.001) | -0.71 (0.553) |